Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR1H4 | Q96RI1 | 20/20 | 0.88 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.61 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.61 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.61 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.61 |
| ▸ | VDR | P11473 | 3/20 | 0.59 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16456903 | 0.92 | NR1H4 (0.75) | NR1H4NR1I2CYP1A2CYP3A4CYP2C9 | |
| SCHEMBL16456754 | 0.90 | NR1H4 (0.72) | NR1H4NR1I2CYP1A2CYP3A4CYP2C9 | |
| SCHEMBL16456795 | 0.90 | NR1H4 (0.72) | NR1H4NR1I2CYP1A2CYP3A4CYP2C9 | |
| SCHEMBL16456727 | 0.90 | NR1H4 (0.72) | NR1H4NR1I2CYP1A2CYP3A4CYP2C9 | |
| SCHEMBL16456716 | 0.90 | NR1H4 (0.72) | NR1H4VDR | |
| SCHEMBL2083132 | 0.89 | NR1H4 (0.71) | NR1H4NR1I2CYP1A2CYP3A4CYP2C9 | |
| Hydrochloric Acid SCHEMBL16456678 | 0.89 | NR1H4 (0.71) | NR1H4NR1I2CYP1A2CYP3A4CYP2C9 | |
| SCHEMBL2082410 | 0.88 | NR1H4 (0.69) | NR1H4 | |
| SCHEMBL2085609 | 0.87 | NR1H4 (0.67) | NR1H4NR1I2CYP1A2CYP3A4CYP2C9 | |
| SCHEMBL16456836 | 0.85 | NR1H4 (0.68) | NR1H4NR1I2CYP1A2CYP3A4CYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1984360-B1 | Compounds and methods for modulating FX-receptors | LILLY CO ELI (US) | 2014-01-15 | — | — | EP | claimed |
| US-7863302-B2 | Compounds and methods for modulating FX-receptors | ELI LILLY AND COMPANY (US) | 2011-01-04 | — | — | US | claimed |
| US-20080306125-A1 | Compounds and Methods for Modulating Fx-Receptors | JPMORGAN CHASE BANK, N.A., AS SUCCESSOR COLLATERAL AGENT | 2008-12-11 | — | — | US | claimed |
| EP-1984360-B1 | Compounds and methods for modulating FX-receptors | LILLY CO ELI (US) | 2014-01-15 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080306125-A1 | Compounds and Methods for Modulating Fx-Receptors | F2R, TBXA2R, PTAFR | NR1H4 65/4885NR1I2 308/4885CYP1A2 660/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.